Risk Factors for Survival in Children with Refractory AML Treated According to AML Relapse Strategies

  • U. Creutzig
  • J. Ritter
  • A. Boos
  • M. Zimmermann
  • C. Bender-Götze
  • K. Stahnke
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 39)

Abstract

About one third of the children treated within the national studies for AML in Germany (BFM studies) experience recurrence of their disease. In order to estimate the value of intensive salvage therapy for children with AML, we analysed the relapse regimens of the BFM study group for outcome and risk factors.

Patients and Treatment. 102 patients (pts.) with first relapse of AML were treated according to BFM relapse strategies: study REZ91 with double induction (mitoxantrone [MITOX]/VP-16 twice, 15 pts.), study REZ93 with induction MITOX/VP-16 plus HD-Ara-C/MITOX (HAM, 28 pts.) followed by a 6-week consolidation and either allogeneic or autologous bone marrow transplantation (BMT). Another 59 patients received either elements of these protocols or other intensive salvage therapy.

Results. Time to relapse was in median 1.1 years, range 0–15 years. Fifty-two of 102 patients (51%) achieved 2nd remission (CR), 10 (10%) partial remission, 37 (36%) were nonresponders, and 3 (3%) died early during salvage therapy. Twenty-seven were alive, in median 2.5 years, range 0.4–7.0 years after relapse, overall survival was 21%, SE 5% after 5 years. The response and survival rate was similar in all treatment groups. MITOX/VP16 induction was well tolerated: 6 of 26 patients in study REZ93 suffered severe infections after 1st induction, compared to 9 of 12 patients after HAM. Fifty patients were transplanted, 43 in 2nd CR, and 7 with residual blasts; 27 patients received an allograft: Twenty-one from a matched sibling (MSD), 1 from a haploid and 5 from a matched unrelated donor (MUD); 23 received an autograft. Results were poor for patients in partial remission, however, promising for autologous BMT in 2nd CR with 10 of 22 patients surviving. Seven of 16 were alive after MSD in 2nd CR and 1 after haploid BMT, 4 of 5 patients died after MUD BMT. Multivariate risk factor analysis for survival after relapse revealed duration until relapse to be the most important factor. The maximum risk-ratio was obtained with a threshhold value of 1.5 years after diagnosis resulting in a 5-year survival of 10%, SE 4% for early relapse, and 40%, SE 10% for late relapse,p logrank 0.0001.

Conclusion. Second CR can be achieved in half of the patients, however, only children with late relapse (>1.5 years after diagnosis) have a realistic chance to be cured.

Keywords

Leukemia Oncol Etoposide Carboplatin Measle 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Stahnke K, Ritter J, Schellong G, Beck JD, Kabisch H, Lampert F, Creutzig U (1992) Rezidivbehandlung bei akuter myeloischer Leukämie im Kindesalter. Eine retrospektive Analyse der in der Studie AML-BFM-83 aufgetretenen Rezidive. Klin Pädiatr 204: 253–257PubMedCrossRefGoogle Scholar
  2. 2.
    Fleischhack G, Graf N, Hasan C, Ackermann M, Breu H, Zernikow B, Bode U (1996) IDA-FLAG ( Idarubicin, Fludarabin, hoch-dosiertes Cytarabin und G- CSF).Ein effektives Therapieschema in der Behandlung von AML-Rezidiven bei Kindern und Jugendlichen. Erste Ergebnisse einer Pilotstudie. Klin Pädiatr 208: 229–235PubMedCrossRefGoogle Scholar
  3. 3.
    Kaplan EL, Meier P (1958) Non-parametric estimation from incomplete observations. J Am Statist Assoc 53: 457–481CrossRefGoogle Scholar
  4. 4.
    Cox DR, Oakes D (1984) Analysis of Survival Data. Chapman and Hall, London.Google Scholar
  5. 5.
    Ciampi A, Hogg SA, Kates L (1986) Stratification by stepwise regression, correspondence analysis and recursive partition: A comparison of three methods of analysis for survival data with covariates. Computational Stat Data Analysis 4: 185CrossRefGoogle Scholar
  6. 6.
    Creutzig U, Ritter J, Schellong G (1990) Identification of two risk groups in childhood acute myelogenous leukemia after therapy intensification in the study AML-BFM-83 as compared with study AML-BFM-78. Blood 75: 1932–1940PubMedGoogle Scholar
  7. 7.
    Creutzig U, Sperling C, Harbott J, Ritter J, Zimmermann M, Löffler H, Riehm H, Schellong G, Ludwig W-D (1995) Clinical significance of surface antigen expression in children with acute myeloid leukemia: results of study AML-BFM87. Blood 86: 3097–3108PubMedGoogle Scholar
  8. 8.
    Creutzig U, Ritter J, Zimmermann M, Schellong G, for the AML-BFM Study Group (1993) Does cranial irradiation reduce the risk for bone marrow relapse in acute myelogenous leukemia (AML): unexpected results of the childhood AML Study BFM-87. J Clin Oncol 11: 279–286PubMedGoogle Scholar
  9. 9.
    Creutzig U, Schrappe M (1996) Akute Leukämien im Kindesalter. Internist 37: 982–993PubMedGoogle Scholar
  10. 10.
    Hurwitz CA, Mounce KG, Grier HE (1995) Treatment of patients with acute myelogenous leukemia: review of clinical trials of the past decade. J Pediatr Hematol Oncol, 17: 185–197PubMedCrossRefGoogle Scholar
  11. 11.
    Santini V, Bernabei PA, Silvestro L, Dal Pozzo O, Bezzini R, Viano I, Gattei V, Saccardi R, Rossi Ferrini P (1989) In vitro chemosensitivity testing of leukemic cells: prediction of response to chemotherapy in patients with acute nonlymphocytic leukemia. Hematol Oncol 7: 287–293PubMedCrossRefGoogle Scholar
  12. 12.
    Steuber CP, Krischer J, Holbrook T, Camitta B, Land V, Sexauer C, Mahoney D, Weinstein H (1996) Therapy of refractory or recurrent childhood acute myeloid leukemia using amsacrine and etoposide with or without azacitidine: A pediatric oncology group randomized phase II study. JCO 14: 1521–1525Google Scholar
  13. 13.
    Amadori S, Picardi A, Fazi P, Testi AM, Petti PC, Montefusco E, Mandelli F (1996) A phase II study of VP-16, intermediate-dose Ara-C and carboplatin ( VAC) in advanced acute myelogenous leukemia and blastic chronic myelogenous leukemia. Leukemia 10: 766–768PubMedGoogle Scholar
  14. 14.
    Hiddemann W, Martin WR, Sauerland C, Hei-necke A, Büchner T (1990) Definition of refractoriness against conventional chemotherapy in acute myeloid leukemia: A proposal based on the results of retreatment by thioguanine, cytosine arabinoside, and daunorubicin (TAD) in 150 patients with relapse after standardized first line therapy. Leukemia 4: 184–188PubMedGoogle Scholar
  15. 15.
    Kantarjian HM, Keating MJ, Walters RS, McCredie KB, Freireich EJ (1988) The characteristics and outcome of patients with late relapse acute myelogenous leukemia. JCO 16. Estey E (1996) Treatment of refractory AML. Leukemia 10: 932–936Google Scholar
  16. 16.
    Tomas JF, Gomez-Garcia de Soria V, Lopez-Lorenzo JL, Aranz R, Figuera A, Camara R, Alegre A, Fernandez-Ranada JM (1996) Autologous or allogeneic bone marrow transplantation for acute myeloblastic leukemia in second complete remission. Importance of duration of first complete remission in final outcome. Bone Marrow Transplantation 17: 979–984PubMedGoogle Scholar
  17. 17.
    Klumper E, Pieters R, Veerman AJ, Huismans DR, Loonen AH, Hahlen K, Kaspers GJ, van Wering ER, Hartmann R, Henze G (1995) In vitro cellular drug resistance in children with relapsed/refractory acute lymphoblastic leukemia. Blood 86: 3861–3868PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1998

Authors and Affiliations

  • U. Creutzig
    • 1
  • J. Ritter
    • 1
  • A. Boos
    • 1
  • M. Zimmermann
    • 1
  • C. Bender-Götze
    • 2
  • K. Stahnke
    • 3
  1. 1.University Children’s Hospital MünsterGermany
  2. 2.University Children’s Hospital MünchenGermany
  3. 3.University Children’s Hospital UlmGermany

Personalised recommendations